MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rh... (ract: 1346 -- Neutralizing I...)

HOME >> BIOLOGY >> TECHNOLOGY

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

Date:10/23/2008

ract:

1346

-- Neutralizing IFN-alpha in SLE affects GMCSF, TNF-alpha, IL-10, IL1-beta

and BAFF signaling pathways - Brandon Higgs, Ph.D., Tuesday, October 28

from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 1340

-- Memory T lymphocytes expressing the inducible costimulator (icos) are

required to maintain the secondary lymphoid tissue architecture in non

human primates - Gianluca Carlesso, Ph.D., Tuesday, October 28 from 9:00

a.m. - 11:00 a.m. in Hall A, Abstract: 1843

-- In vitro properties of CAM-3001, a human anti GM-CSF receptor antibody

for the treatment of patients with rheumatoid arthritis - Matthew

Sleeman, Ph.D., Tuesday, October 28 from 9:00 a.m. - 11:00 a.m. in Hall

A, Abstract: 1338

-- Use of a SOCS3 ex-vivopharmacodynamic quantitative RT-PCR assay for

CAM-3001, a new antibody therapy for the treatment of rheumatoid

arthritis - Jo Woods, Ph.D., Tuesday, October 28 from 9:00 a.m. - 11:00

a.m. in Hall A, Abstract: 1339

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.

0

GOOD

Page: 1 2 3
Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
2. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
3. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
4. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
5. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
6. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
7. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
8. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
9. Seneca Valley High School Student Receives Science Award From MedImmune
10. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
11. MedImmune Submits Biologics License Application to FDA for Motavizumab

Post Your Comments:

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rh...(ract: 1346 -- Neutralizing I...)